Darlifarnib

Darlifarnib
Clinical data
Other names	KO-2806
Identifiers
	IUPAC name (3S)-3-Amino-3-(1-methyl-1H-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-22,44-dicarbonitrile;
CAS Number	3065226-39-0;
PubChem CID	169292214;
UNII	9PE5MSX2YS;
KEGG	D13346;
Chemical and physical data
Formula	C29H20N6O
Molar mass	468.520 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C=NC=C1[C@@]2(C3=CC(=C(C=C3)C#N)COC4=CC=CC(=C4)C5=C6C=C2C=CC6=NC(=C5)C#N)N;
	InChI InChI=InChI=1S/C29H20N6O/c1-35-17-33-15-28(35)29(32)21-6-5-19(13-30)20(9-21)16-36-24-4-2-3-18(10-24)25-12-23(14-31)34-27-8-7-22(29)11-26(25)27/h2-12,15,17H,16,32H2,1H3/t29-/m0/s1; Key:GWKGWWBQKOIPNP-LJAQVGFWSA-N;

Darlifarnib is an investigational new drug that is being developed by Kura Oncology, Inc. for the treatment of solid tumors. It is a farnesyltranstransferase inhibitor.^[1]^[2]^[3]

References

↑ "Darlifarnib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Patel HV, Smith AE, Chan S, Gasendo JG, Jombik A, Greer JE, et al. (May 2026). "The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition". Cancer Research. 86 (9): 2273–2285. doi:10.1158/0008-5472.CAN-25-2764. PMC 13136870. PMID 41661652.
↑ Gasendo JG, Chan S, Patel HV, Smith AE, Kessler L, Liu YA, et al. (March 2026). "Farnesyl transferase inhibitor KO-2806 (darlifarnib) enhances the anti-tumor activity of tyrosine kinase inhibitors in RCC". Molecular Cancer Therapeutics: OF1–OF11. doi:10.1158/1535-7163.MCT-25-0449. PMID 41881565.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.